Skip to main content
. 2021 Nov 30;9(1):e1092. doi: 10.1212/NXI.0000000000001092

Figure 1. COVID-19 Severity* and Outcome in Fingolimod-Treated People Living With Multiple Sclerosis.

Figure 1

*COVID-19 severity was assessed based on both the FDA and WHO COVID-19 criteria. Information as per the last follow-up. Numbers in parenthesis show—(patients hospitalized; patients requiring ventilation or ICU admission). FDA = US Food and Drug Administration; ICU = intensive care unit; WHO = World Health Organization.